A detailed history of Emerald Advisers, LLC transactions in Acadia Pharmaceuticals Inc stock. As of the latest transaction made, Emerald Advisers, LLC holds 830,829 shares of ACAD stock, worth $13.5 Million. This represents 0.53% of its overall portfolio holdings.

Number of Shares
830,829
Previous 808,831 2.72%
Holding current value
$13.5 Million
Previous $13.1 Million 2.72%
% of portfolio
0.53%
Previous 0.59%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 29, 2024

BUY
$15.14 - $19.14 $333,049 - $421,041
21,998 Added 2.72%
830,829 $12.8 Million
Q2 2024

Aug 06, 2024

SELL
$14.62 - $18.42 $12.3 Million - $15.5 Million
-842,293 Reduced 51.01%
808,831 $13.1 Million
Q1 2024

May 08, 2024

BUY
$17.79 - $30.86 $98,894 - $171,550
5,559 Added 0.34%
1,651,124 $30.5 Million
Q4 2023

Feb 05, 2024

SELL
$20.78 - $31.77 $737,419 - $1.13 Million
-35,487 Reduced 2.11%
1,645,565 $51.5 Million
Q3 2023

Oct 26, 2023

BUY
$20.84 - $33.47 $1.34 Million - $2.15 Million
64,100 Added 3.96%
1,681,052 $35 Million
Q2 2023

Jul 25, 2023

BUY
$17.8 - $25.65 $2.14 Million - $3.09 Million
120,392 Added 8.04%
1,616,952 $38.7 Million
Q1 2023

May 04, 2023

BUY
$16.32 - $20.92 $2.85 Million - $3.65 Million
174,414 Added 13.19%
1,496,560 $28.2 Million
Q4 2022

Feb 03, 2023

SELL
$14.2 - $18.63 $106,216 - $139,352
-7,480 Reduced 0.56%
1,322,146 $21 Million
Q3 2022

Oct 25, 2022

BUY
$14.11 - $18.27 $6.62 Million - $8.57 Million
468,877 Added 54.47%
1,329,626 $21.8 Million
Q2 2022

Jul 29, 2022

BUY
$13.01 - $27.22 $936,863 - $1.96 Million
72,011 Added 9.13%
860,749 $12.1 Million
Q1 2022

Apr 29, 2022

BUY
$20.94 - $27.5 $1.5 Million - $1.96 Million
71,420 Added 9.96%
788,738 $19.1 Million
Q4 2021

Feb 02, 2022

BUY
$16.79 - $27.09 $12 Million - $19.4 Million
717,318 New
717,318 $16.7 Million

Others Institutions Holding ACAD

About ACADIA PHARMACEUTICALS INC


  • Ticker ACAD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 161,843,008
  • Market Cap $2.63B
  • Description
  • ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's p...
More about ACAD
Track This Portfolio

Track Emerald Advisers, LLC Portfolio

Follow Emerald Advisers, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Emerald Advisers, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Emerald Advisers, LLC with notifications on news.